Sana Kliniken Duisburg GmbH
- Address
- Zu Den Rehwiesen 7-9, Wanheimerort, 47055 Duisburg, Germany
Sana Kliniken Duisburg GmbH - Specialized Oncology and Hematology Research Center
Sana Kliniken Duisburg GmbH is a leading clinical research facility with distinguished expertise in pediatric and adult neuro-oncology, hematologic disorders, and immunotherapy. The center participates in international collaborative trials, demonstrating a strong commitment to advancing treatment protocols for complex neurological tumors and rare blood disorders. Their research portfolio spans from innovative surgical approaches to cutting-edge immunotherapeutic interventions.
- Pediatric and adult brain tumors, including medulloblastoma, ependymoma, and glioblastoma
- Novel immunotherapy approaches using dendritic cell vaccines and personalized cancer treatment
- Inflammatory bowel disease research, particularly ulcerative colitis
- Rare hematologic conditions including congenital antithrombin deficiency
The center's participation in SIOP (International Society of Paediatric Oncology) trials highlights its role in developing risk-stratified treatment protocols for childhood brain tumors. Research initiatives focus on integrating molecular profiling with conventional therapies, including advanced radiotherapy techniques and chemotherapy regimens. The facility also investigates histone deacetylase inhibitors and other targeted therapies, while maintaining capabilities in evaluating hemostatic replacement therapies for patients undergoing surgical procedures.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Centre Leon Berard1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sana Kliniken Duisburg GmbH
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of SAR441566 in Adults with Moderate-to-Severe Ulcerative Colitis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | Jun 2025 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 4 | Unknown | 2015-06-02 | 2024-09-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.